Prolintane is an amphetamine-related CNS stimulant and norepinephrine-dopamine reuptake inhibitor that has been used for the treatment of narcolepsy and attention deficit hyperactivity disorder in Africa, Australia, and Europe. Under the trade-name "Katovit", prolintane was commercialized by the Spanish pharmaceutical company, FHER. Katovit was sold until 2001 and was most often used by students and workers as a stimulant to provide energy, promote alertness and concentration. The use of prolintane as a doping agent in athletics has been noted worldwide. Prolintane, like many amphetamine derivatives, increases the concentration of dopamine in the synaptic cleft. Adverse effects of the drug include insomnia, nervousness, irritability, and dizziness. Overdoses of prolintane may cause hallucinations, psychosis, and death. Individuals who abuse prolintane risk becoming dependent as tolerance may develop.